Introduction to Cancer Biology (Part 4): Angiogenesis

As the growth expands, it eventually gets to a size where it calls for extra vasculature in order to sustain continued growth. To accomplish this, tumor cells eliminate specific healthy proteins that stimulate capillary development into and also around the lump – a procedure called angiogenesis. This animation is the final and 4th component of the series “An Introduction to Cancer Biology”.

REFERRALS:
The trademarks of cancer cells. Cell.

Evaluation of epidermal growth element receptor biology. Int J Radiat Oncol Biol Phys.

3. Gerharz CD, Ramp U, Reinecke P, et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Hints to the duty of paracrine, autocrine and juxtacrine interactions in epithelioid sarcoma. Eur J Cancer. 2000 Jun; 36( 9 ):1171 -9.

4. Potapova O, Fakhrai H, Mercola D. Growth variable PDGF-B/v-sis gives a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells empty of receptors: proof for an autocrine, yet not a paracrine, system. Int J Cancer. 1996 May 29; 66( 5 ):669 -77.

5. Andl CD, Mizushima T, Nakagawa H, et al. Epidermal development variable receptor mediates increased cell spreading, migration, as well as gathering in esophageal keratinocytes artificial insemination as well as in vivo. J Biol Chem. 2003 Jan 17; 278( 3 ):1824 -30.

Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. 1987 Jul 10; 237( 4811 ):178 -82.

7. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal development factor ligand-independent, unregulated, cell-transforming capacity of a naturally taking place human mutant EGFRvIII gene. Cell Growth Differ. 1995 Oct; 6( 10 ):1251 -9.

Egeblad M, Mortensen OH, Jaattela M. Truncated ErbB2 receptor improves ErbB1 signaling and also generates relatively easy to fix, ERK-independent loss of epithelial morphology. Int J Cancer.

9. Lage A, Crombet T, González G. Targeting epidermal development variable receptor signaling: early results and also future trends in oncology. Ann Med. 2003; 35( 5 ):327 -36.

Adjei AA, Hidalgo M. Intracellular signal transduction pathway healthy proteins as targets for cancer cells treatment. J Clin Oncol.

Raf: a critical target for therapeutic advancement against cancer cells. J Clin Oncol.

TOR, a main controller of cell growth. Cell.

13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb; 2( 2 ):127 -37.

Nat Rev Cancer. 2002 Apr; 2( 4 ):277 -88.

15. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M. An introduction to the molecular mechanisms of apoptosis. Ann N Y Acad Sci. 2003 Dec; 1010:1 -8.

16. Veiby OP, Read MA. Chemoresistance: effect of nuclear factor (NF)-kappaB inhibition by tiny interfering RNA. Clin Cancer Res. 2004 May 15; 10( 10 ):3333 -41.

17. Foo P. Metastasis: The trip of mobile cancer cells. Harvard Science Review. Spring 2002; 30-2.

Function of the vascular endothelial growth variable path in tumor development and also angiogenesis. J Clin Oncol.

19. Ellis LM. Epidermal development element receptor in lump angiogenesis. Hematol Oncol Clin North Am. 2004 Oct; 18( 5 ):1007 -21.

20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and also Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004 Jun 3; 350( 23 ):2335 -42.

Activity of SU11248, a multitargeted prevention of vascular endothelial development variable receptor and also platelet-derived development element receptor, in people with metastatic renal cell carcinoma. J Clin Oncol.